US COVID-19 Relief Law Boosts Pharmaceutical Manufacturing Programs; Is More To Come?
Executive Summary
$10bn here and $6bn there on top of what’s left from earlier CARES Act gives government more options on COVID-19 medical countermeasures.
You may also be interested in...
US Bills Aim To Reduce Pharma Manufacturing Reliance On China
A US bipartisan Senate bill and House proposal aim to bring pharma manufacturing from China to closer to home, through partnerships with American universities to train the workforce and develop technologies.
Time Is Now To Seek US Funding, Financing To Expand Domestic COVID-19 Vaccine Supply Chain
BARDA and Development Financing Corp. officials provide insights into window of opportunity for partnering on manufacturing scale-up.
Public-Private Consortium To Strengthen Essential Medicines Supply Under White House Initiative
President Biden’s 100-day plan relies on Defense Production Act authorities to increase resilience of critical domestic pharmaceutical supplies.